Get our Free Patent Expiration Newsletter

Serving leading biopharmaceutical companies globally:

Johnson and Johnson
Mallinckrodt
Harvard Business School
McKesson
Colorcon
Express Scripts

Last Updated: November 15, 2019

DrugPatentWatch Database Preview

CLINICAL TRIALS PROFILE FOR RAPAFLO

See Plans and Pricing

« Back to Dashboard

All Clinical Trials for Rapaflo

Trial ID Title Status Sponsor Phase Start Date Summary
NCT00224107 A New Drug for Benign Prostatic Hyperplasia (BPH) Compared With Placebo Completed Watson Pharmaceuticals Phase 3 2005-05-01 A new drug for benign prostatic hyperplasia is compared to placebo for to determine if it is safe and effective. The study lasts approximately 20 weeks.
NCT00224120 A New Drug for Benign Prostatic Hyperplasia (BPH) Compared With Placebo Completed Watson Pharmaceuticals Phase 3 2005-05-01 A new drug for benign prostatic hyperplasia is compared to placebo for to determine if it is safe and effective. The study lasts approximately 20 weeks.
NCT00224133 The Evaluation of the Safety of a New Drug for Benign Prostatic Hyperplasia Used for 9 Months Completed Watson Pharmaceuticals Phase 3 2005-09-01 A new drug for benign prostatic hyperplasia is used for 9 months to determine its long-term safety.
NCT00740779 Use of Silodosin to Treat Moderate to Severe Abacterial Chronic Prostatitis/Chronic Pelvic Pain Syndrome. Completed Watson Pharmaceuticals Phase 2 2008-09-01 The primary objective is to compare the efficacy of silodosin 4 and 8 mg once daily with placebo in the treatment of subjects with moderate to severe abacterial chronic prostatitis/chronic pelvic pain syndrome during a 12 week treatment period. The secondary objective is to compare the safety of silodosin 4 and 8 mg once daily with placebo.
>Trial ID >Title >Status >Phase >Start Date >Summary

Clinical Trial Conditions for Rapaflo

Condition Name

Condition Name for Rapaflo
Intervention Trials
Benign Prostatic Hyperplasia 2
Nocturia 1
Urinary Problems 1
Benign Prostatic Hyperplasia (BPH) 1
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Condition MeSH

Condition MeSH for Rapaflo
Intervention Trials
Hyperplasia 4
Prostatic Hyperplasia 4
Syndrome 1
Somatoform Disorders 1
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Clinical Trial Locations for Rapaflo

Trials by Country

Trials by Country for Rapaflo
Location Trials
United States 116
Canada 1
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Trials by US State

Trials by US State for Rapaflo
Location Trials
New York 5
Pennsylvania 5
California 5
Washington 5
Oklahoma 4
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Clinical Trial Progress for Rapaflo

Clinical Trial Phase

Clinical Trial Phase for Rapaflo
Clinical Trial Phase Trials
Phase 4 1
Phase 3 4
Phase 2 2
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Clinical Trial Status

Clinical Trial Status for Rapaflo
Clinical Trial Phase Trials
Completed 5
Recruiting 1
Terminated 1
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Clinical Trial Sponsors for Rapaflo

Sponsor Name

Sponsor Name for Rapaflo
Sponsor Trials
Watson Pharmaceuticals 5
Albert Einstein Healthcare Network 1
Sir Mortimer B. Davis - Jewish General Hospital 1
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Sponsor Type

Sponsor Type for Rapaflo
Sponsor Trials
Industry 5
Other 2
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Make Better Decisions: Try a trial or see plans & pricing

Serving leading biopharmaceutical companies globally:

Colorcon
McKesson
Boehringer Ingelheim
Baxter
Medtronic
Johnson and Johnson

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.